Abstract
Large scale in silico clinical development will only become a reality after some effort is exerted; some partial solutions (SB and BI tools mentioned in previous chapters) already exist and first attempts have been made. We acknowledge here that we are NOT in square zero and that in silico technologies have been, and are already being, used in clinical trial design and execution, used in simulation studies for adaptive trials, and used to identify patient subpopulations and markers for enrichment strategies. This goal will require a concentrated effort by all players, with considerable investment from the pharma industry and governments.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Lalonde RL, Kowalski KG, Hutmacher MM, Ewy W, Nichols DJ, Milligan PA, Corrigan BW, Lockwood PA, Marshall SA, Benincosa LJ, Tensfeldt TG, Parivar K, Amantea M, Glue P, Koide H, Miller R (2007) Model-based drug development. Clin Pharmacol Ther 82(1):21–32
Powell JR, Gobburu JV (2007) Pharmacometrics at FDA: evolution and impact on decisions. Clin Pharmacol Ther 82(1):97–102
Gobburu JV, Lesko LJ (2009) Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol 49:291–301
Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275–291
Allerheiligen SR (2010) Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin Pharmacol Ther 88(1):135–137
Wetherington JD, Pfister M, Banfield C, Stone JA, Krishna R, Allerheiligen S, Grasela DM (2010) Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development. J Clin Pharmacol 50(9 Suppl):31S–46S
Suryawanshi S, Zhang L, Pfister M, Meibohm B (2010) The current role of model-based drug development. Expert Opin Drug Discov 5(4):311–321
Keizer RJ, Schellens JH, Beijnen JH, Huitema AD (2011) Pharmacodynamic biomarkers in model-based drug development in oncology. Curr Clin Pharmacol 6(1):30–40
Nasr MM (2006) FDA, DIA meeting Philadelphia, PA, USA
Lutze P, Román-Martinez A, Woodley JM, Gani R (2010) A systematic synthesis and design methodology to achieve process intensification in (bio) chemical processes. In: Pierucci S, Buzzi Ferraris G (eds) 20th European symposium on computer aided process engineering—ESCAPE20, Elsevier
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2012 The Author(s)
About this chapter
Cite this chapter
Prokop, A., Michelson, S. (2012). Development: Preclinical Model Based Drug Development. In: Systems Biology in Biotech & Pharma. SpringerBriefs in Pharmaceutical Science & Drug Development, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-2849-3_10
Download citation
DOI: https://doi.org/10.1007/978-94-007-2849-3_10
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-2848-6
Online ISBN: 978-94-007-2849-3
eBook Packages: MedicineMedicine (R0)